Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
October 28, 2021 at 05:57 am EDT
Share
Jiangsu Sihuan Bioengineering Co., Ltd reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 236.21 million compared to CNY 354.41 million a year ago. Revenue was CNY 236.21 million compared to CNY 354.41 million a year ago. Net loss was CNY 22.78 million compared to net income of CNY 21.75 million a year ago. Basic loss per share from continuing operations was CNY 0.0221 compared to basic earnings per share from continuing operations of CNY 0.0211 a year ago. Diluted loss per share from continuing operations was CNY 0.0221 compared to diluted earnings per share from continuing operations of CNY 0.0211 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
